OpenAI’s latest model, o1, helped a geneticist shave weeks off the diagnostic workflow for obscure medical cases. Catherine Brownstein demonstrated the tool on a handful of patients with undiagnosed rare diseases, using it to prioritize candidate gene variants and suggest likely pathogenicity. The pilot showed a noticeable speedup compared with the manual review process she typically follows.
The demo matters because rare‑disease diagnosis has long been a bottleneck in precision medicine. Faster variant triage could mean earlier treatment decisions and less costly “diagnostic odysseys” for families. While OpenAI touts o1 as a general‑purpose reasoning engine, its application to genomics hints that the same approach could be repurposed across other data‑intensive medical tasks.
The move follows a series of AI‑driven genetics milestones, from DeepMind’s AlphaFold protein‑structure predictions to large‑language‑model‑based variant annotation tools. Unlike those, o1 is marketed as a reasoning‑first system rather than a specialised predictor, which may let it adapt more quickly to new disease frames. Still, the demonstration was limited to a small cohort, and real‑world adoption will depend on regulatory clearance and integration with existing laboratory pipelines. The excitement will likely be tempered until peer‑reviewed results appear.